Myeloma After Relapse: What New Research Means for Patients

Dr. Krina K. Patel of The University of MD Anderson Cancer Center discusses encouraging new data from the MAJESTIC-3 clinical trial, which studied a combination of two immunotherapies for people with multiple myeloma after their first relapse. She explains how this approach works, what makes the results so promising, and why supportive care is essential to safely manage treatment. Dr. Patel also shares practical insights to help patients understand where this option may fit into their care journey, offering hope while emphasizing thoughtful, individualized decision-making. Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to offer trusted information to empower anyone impacted by cancer, through health equity, health literacy and shared decision-making. Subscribe now to receive the latest news on cancer treatment and research: https://powerfulpatients.org/stay-upd...